「Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation」の関連論文
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
-
PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
-
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
-
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer
-
Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer
-
転移性尿路上皮癌に対するGC療法における, Gemcitabine投与後の発熱の臨床的意義の検討: 多施設共同後ろ向き研究
-
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
-
MDM4 as a prognostic factor for patients with gastric cancer with low expression of p53:immunohistochemical study of p53, MDM2, and MDM4
-
Profiling of Naquotinib, a Small Molecule Kinase Inhibitor, as EGFR and BTK Inhibitor
-
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
-
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
-
Studies on the Enhancement of Antitumor Effect by Drug Combination in Molecular-Targeted Therapy of Cancer
-
Neutrophil–lymphocyte Ratio and Histological Response Correlate With Prognosis of Gastric Cancer Undergoing Neoadjuvant Chemotherapy
-
Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer
-
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial
-
Expressions of ezrin, ERK, STAT3, and AKT in tongue cancer and association with tumor characteristics and patient survival.
-
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
-
Programmed death ligand-1 expression and occult lymph node metastasis in non-small cell lung cancer
-
Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age
-
An HSP90 inhibitor overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs
-
Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors
-
Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis
-
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
-
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study
-
分子標的薬時代における転移性腎癌の腫瘍縮小率が予後に与える影響
-
The baseline recurrence risk of patients with intermediate-risk cervical cancer.
-
Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients
-
Significance of Wnt/β-Catenin Signal Activation for Resistance to Neoadjuvant Chemoradiotherapy in Rectal Cancer
-
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
-
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer
-
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer
-
Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure
-
MYC Upregulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer
-
Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
-
Comparison of efficacy and safety outcomes of anticancer drugs between Japanese patients and the overall population in multi-regional clinical trials
-
Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma
-
Relationship of Mitochondrial-Related Protein Expression with the Differentiation, Metastasis, and Poor Prognosis of Oral Squamous Cell Carcinoma
-
Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA
-
The Elevation in Preoperative Procalcitonin Is Associated with a Poor Prognosis for Patients Undergoing Resection for Colorectal Cancer.
-
Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
-
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
-
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
-
Malignant Progression of Diffuse Low-grade Gliomas : A Systematic Review and Meta-analysis on Incidence and Related Factors.
-
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
-
外科的に切除された膵癌におけるST2発現の臨床病理学的及び予後との関連性の検討
-
Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study
-
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
-
Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer